CXCR2 and ovarian cancer: The CXCR2-binding chemokines CXCL1 and CXCL8, as well as CXCR2 itself, have also been a focus for drug development and show promise for the treatment of melanoma, breast cancer, ovarian cancer, and pancreatic cancer in preclinical models [32,33,34,35,36,37].